TrialBritish journal of cancer2018

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.

Davide Melisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.